Interstitial Lung Disease in the Connective Tissue Diseases - 25/02/12

Doi : 10.1016/j.ccm.2012.01.004

Danielle Antin-Ozerkis, MD ^a,^⁎ , Ami Rubinowitz, MD ^b, Janine Evans, MD ^c, Robert J. Homer, MD, PhD ^d, Richard A. Matthay, MD ^e
^a Yale Interstitial Lung Disease Program, Pulmonary & Critical Care Medicine Section, Department of Internal Medicine, Yale University School of Medicine, 15 York Street, LLCI 101B, New Haven, CT 06510, USA
^b Department of Diagnostic Radiology, Yale University School of Medicine, PO Box 208042, Tompkin’s East 2, New Haven, CT 06520-8042, USA
^c Rheumatology Section, Department of Internal Medicine, Yale University School of Medicine, PO Box 208031, 300 Cedar Street, TAC S-425D, New Haven, CT 06520-8031, USA
^d Yale University School of Medicine, PO Box 208023, 310 Cedar Street, LH 108, New Haven, CT 06520-8023, USA
^e Pulmonary & Critical Care Medicine Section, Department of Internal Medicine, Yale University School of Medicine, PO Box 208057, 300 Cedar Street, New Haven, CT 06520-8057, USA

Corresponding author.

Résumé

The connective tissue diseases (CTDs) are inflammatory, immune-mediated disorders in which interstitial lung disease (ILD) is common and clinically important. Interstitial lung disease may be the first manifestation of a CTD in a previously healthy patient. CTD-associated ILD frequently presents with the gradual onset of cough and dyspnea, although rarely may present with fulminant respiratory failure. Infection and drug reaction should always be ruled out. A diagnosis of idiopathic ILD should never be made without a careful search for subtle evidence of underlying CTD. Treatment of CTD-ILD typically includes corticosteroids and immunosuppressive agents.

Le texte complet de cet article est disponible en PDF.

Keywords : Connective tissue, Interstitial lung disease, Inflammation, Immunity